argenx SE header image

argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2026-05-25)

EUR 705.80+0.68%

argenx SE
UMushroom community rating:

4.86 3 votes No rating yet

NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

37.2%1Y

88.3%3Y

221%5Y

Performance

33.3%1Y

40.1%3Y

38.5%5Y

Volatility

50965 M

Market cap (USD)

29,847

Daily traded volume (Shares)

600 / 594.2

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.86

3 votes

Performance:

4.71

Innovation:

5.00

Society:

4.86

Nature:

3.57

Laura Sofie Tohver

United Kingdom, 11 Nov 2025

Emerging technology and nice returns

Viktor Stockel

Switzerland, 30 Oct 2025

Argenx SE is a commercial-stage, global biopharmaceutical company focused on immunology, particularly therapies for severe autoimmune diseases.

Claudia Stadelmann

Switzerland, 05 Mar 2025

Geheimtipp belgisches Biotech mit spannender Pipeline

EQUITIES OF THE SAME SECTOR

Halma PLC

Halma PLC Valor: 387465

Annual Return

-50%0%+50%

Risk level

110

1.60%GBP 45.64

Grifols, SA

Grifols, SA Valor: 30689493

Annual Return

-50%0%+50%

Risk level

110

2.41%EUR 9.70

Elecnor SA

Elecnor SA Valor: 3982294

Annual Return

-50%0%+50%

Risk level

110

2.95%EUR 40.10

Hesai Group

Hesai Group Valor: 124938034

Annual Return

-50%0%+50%

Risk level

110

-1.29%USD 20.63

q.beyond AG

q.beyond AG Valor: 1062813

Annual Return

-50%0%+50%

Risk level

110

1.06%EUR 3.80

Kyndryl Holdings Incorporation

Kyndryl Holdings Incorporation Valor: 114282708

Annual Return

-50%0%+50%

Risk level

110

1.82%USD 12.29

DigitalOcean Holdings Inc

DigitalOcean Holdings Inc Valor: 110302680

Annual Return

-50%0%+50%

Risk level

110

0.07%USD 158.46

PagerDuty Inc

PagerDuty Inc Valor: 46980799

Annual Return

-50%0%+50%

Risk level

110

2.13%USD 7.20

Eli Lilly & Co

Eli Lilly & Co Valor: 947556

Annual Return

-50%0%+50%

Risk level

110

2.24%USD 1,078.24

Array Technologies Inc

Array Technologies Inc Valor: 57373259

Annual Return

-50%0%+50%

Risk level

110

3.41%USD 8.48

SIX

FactSet

Clearbit

Logos provided by Clearbit